GlassScriptPhysician profile
David M Rose
NPI 1750471066
$252,662.49
in general payments reported to CMS, 2019-2025
13 companies · $153K in 2025
The $153K reported for 2025 was more than what 99% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $21K · 2021: $14K · 2022: $5,428 · 2023: $6,701 · 2024: $52K · 2025: $153K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $167K · Travel and Lodging: $34K · Food and Beverage: $5,603 · Consulting Fee: $5,200 · Education: $66.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $166,587.00 |
| Travel and Lodging | $33,998.70 |
| Food and Beverage | $5,603.43 |
| Consulting Fee | $5,200.00 |
| Education | $66.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $191,152.16 | 2020-2025 | Arexvy, Shingrix, Nucala |
| Astrazeneca Pharmaceuticals LP | $56,273.04 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $2,685.66 | 2019-2025 | |
| Boston Scientific Corporation | $1,756.42 | 2022-2024 | Watchman Flx |
| Pharming Healthcare, INC. | $175.24 | 2023-2025 | Ruconest, Joenja |
| Adma Biomanufacturing LLC | $150.00 | 2024 | |
| Csl Behring | $125.00 | 2022 | |
| Alk-Abello, INC | $123.26 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $89.90 | 2025 | Dupixent |
| Pfizer INC. | $38.48 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.38 | 2025 | Glassia |
| Gilead Sciences, INC. | $30.12 | 2019 | |
| Blueprint Medicines Corporation | $28.83 | 2025 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.